News

Under terms of the exclusive, multi-year agreement, Medison Pharma will commercialize products from PharmAthene’s biodefense portfolio and will be responsible for overseeing regulatory approval, marketing, and distribution activities

Proceeds from the offering will be used to advance Knopp’s discovery research targeting mitochondrial mechanisms of neurodegeneration and to complete an ongoing Phase II study of KNS-760704 in

The multi-center, double-blind, placebo controlled trial is a dose response study comparing 400mg and 600mg of Droxidopa to placebo in a total of 75 patients. Following a two-week

Revenue recognition for the announced new business contracts is expected to begin in the fourth quarter of 2008 on a proportional basis as services are performed on each

The new patent provides protection relating to rifaximin for treating irritable bowel syndrome (IBS) caused by small intestinal bacterial overgrowth. Salix has an exclusive license to this patent

The six month Fast 4Ward study met primary and secondary endpoints, and showed 400mg certolizumab pegol, given every four weeks as subcutaneous monotherapy, significantly reduced signs, symptoms and

Randy Moseley, who was serving as interim CEO until a permanent replacement was named, simultaneously resigned as interim CEO but will continue in his role as chairman of

The Phase II study was a randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of MBX-8025, both alone and in combination with atorvastatin (marketed as Lipitor),

The agreement, which spans more than three dozen countries, excluding the US and Japan, will help to transform Lilly’s R&D organization as they seek to drive productivity, gain